(±)-Chlormezanone
-
(±)-Chlormezanone
structure -
-
CAS No:
80-77-3
-
Formula:
C11H12ClNO3S
-
Chemical Name:
(±)-Chlormezanone
-
Synonyms:
4H-1,3-Thiazin-4-one,2-(4-chlorophenyl)tetrahydro-3-methyl-,1,1-dioxide;4H-1,3-Thiazin-4-one,2-(p-chlorophenyl)tetrahydro-3-methyl-,1,1-dioxide;Chlormethazone;2-(4-Chlorophenyl)-3-methyl-4-metathiazanone-1,1-dioxide;2-(p-Chlorophenyl)tetrahydro-3-methyl-4H-1,3-thiazin-4-one 1,1-dioxide;2-(p-Chlorphenyl)-3-methyl-1,3-perhydrothiazin-4-on-1,1-dioxide;Phenarol;Trancopal;Chlormethazanone;Chlormezanone;2-(p-Chlorophenyl)-3-methyl-1,3-perhydrothiazin-4-one 1,1-dioxide;Mio-Sed;Tanafol;Fenarol;Rilansyl;Rilaquil;Rilassol;Muskel Trancopal;(±)-Chlormezanone;dl-Chlormezanone;(±)-Fenarol;Supotran;Suprotran;Rilasol;Dichloromezanone;Lobak;Trancote;Banabin-Sintyal;Rexan;Alinam;Transanate;NSC 169108;2-(4-Chlorophenyl)-3-methyl-1,1-dioxo-1,3-thiazinan-4-one;2-(4-Chlorophenyl)-3-methyl-1λ6,3-thiazinane-1,1,4-trione;2-(4-Chlorophenyl)-3-methyl-1,3-thiazinan-4-one1,1-dioxide;2-(4-Chlorophenyl)-3-methyl-1,3-thiazinan-4-one 1,1-dioxide;102818-65-5;1024161-45-2
- Categories:
-
CAS No:
Description
Chlormezanone resembles benzodiazepine. The action of Chlormezanone is similar to benzodiazepine-type agents. Chlormezanone is used as an anxiolytic and a muscle relaxant.
Solid
Chlormezanone is a 1,3-thiazine that is 1,3-thiazinan-4-one S,S-dioxide in which a hydrogen at position 2 is substituted by a 4-chlorophenyl group and the hydrogen attached to the nitrogen is substituted by methyl. A non-benzodiazepine muscle relaxant, it was used in the management of anxiety and in the treatment of muscle spasms until being discontinued worldwide by its manufacturer in 1996, due to rare but serious cutaneous reactions. It has a role as an anxiolytic drug, a muscle relaxant and an antipsychotic agent. It is a 1,3-thiazine, a lactam, a sulfone and a member of monochlorobenzenes.|A non-benzodiazepine that is used in the management of anxiety. It has been suggested for use in the treatment of muscle spasm.
(±)-Chlormezanone Basic Attributes
273.74
273.74
201-307-4
C14WB33Y0S|4BU37OM8KL
759569|169108
DTXSID3022798
CRYSTALS
M - Musculo-skeletal system
Characteristics
62.8
1.1
Solid
1.4±0.1 g/cm3
116.2-118.2 °C
534.5°C at 760 mmHg
277.1±30.1 °C
1.580
1.61e+00 g/L
Store at RT
158.2 Ų [M+H]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards]
Safety Information
XJ1050000
P264, P270, P301+P312, P330, P501
H302
|Warning|H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]|P264, P270, P301+P312, P330, and P501|Aggregated GHS information provided by 158 companies from 2 notifications to the ECHA C&L Inventory.
Toxicity
Symptoms of overdose include drowsiness, weakness, nausea, dizziness, abdominal pain, cerebral oedema and renal tubular necrosis, hyperglycaemia and hypoglycaemia, liver damage, encephalopathy, coma and death.
CHLORMEZANONE MAY LOWER TOLERANCE OF PATIENTS TO ALCOHOL...POSSIBLE ADDITIVE EFFECTS /WITH CHLORMEZANONE &/ CNS DEPRESSANTS SUCH AS ALCOHOL, PHENOTHIAZINES, BARBITURATES, NARCOTICS, OTHER PSYCHOTHERAPEUTIC AGENTS, & MONOAMINE OXIDASE INHIBITORS.
| Name | Type of Test | Exposure Route | Species Observed | Dose/Duration | Toxic Effects | Reference |
|---|---|---|---|---|---|---|
| ACUTE TOXICITY DATA | LDLo - Lowest published lethal dose | Oral | Human - woman | 20 gm/kg | Lungs, Thorax, or Respiration--emphysema Lungs, Thorax, or Respiration--acute pulmonary edema Lungs, Thorax, or Respiration--other changes |
Hochudoku. (Nippon Hochudoku Gakkai, c/o Kyushu Daigaku Igakubu Hoigaku Kyoshitsu, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812, Japan) V.8- 1990- Volume(issue)/page/year: 9,168,1991 |
| ACUTE TOXICITY DATA | TDLo - Lowest published toxic dose | Oral | Human - man | 157 mg/kg | Sense Organs and Special Senses (Eye)--mydriasis (pupillary dilation) Behavioral--ataxia Behavioral--coma |
British Medical Journal. (British Medical Assoc., BMA House, Tavistock Sq., London WC1H 9JR, UK) V.1- 1857- Volume(issue)/page/year: 292,732,1986 |
| ACUTE TOXICITY DATA | TDLo - Lowest published toxic dose | Oral | Human - woman | 140 mg/kg | Behavioral--coma Vascular--BP lowering not characterized in autonomic section |
British Medical Journal. (British Medical Assoc., BMA House, Tavistock Sq., London WC1H 9JR, UK) V.1- 1857- Volume(issue)/page/year: 286,845,1983 |
Drug Information
Used in the management of anxiety and in the treatment of muscle spasm.
Anti-Anxiety Agents; Muscle Relaxants, Central|...ADMIN IV HAVE ESTABLISHED VALUE IN TREATING ACUTE MUSCLE SPASMS ASSOC WITH TRAUMA & INFLAMMATION. ...ALSO BENEFICIAL IN PRODUCING MUSCLE RELAXATION FOR CERTAIN ORTHOPEDIC MANIPULATIONS. ...MAY TEMPORARILY ABATE SOME OF SYMPTOMS OF CEREBRAL PALSY... /CENTRALLY ACTING MUSCLE RELAXANTS/|MANY AGENTS WITH MUSCLE RELAXANT PROPERTIES PRODUCE NOTABLE SEDATION IN ORDINARY ORAL DOSES. SUCH AGENTS ENJOY PARTICULARLY WIDE USE IN TREATMENT OF MUSCLE TENSION & PAINS ASSOC WITH ANXIETY STATES & PSYCHOSOMATIC DISORDERS. /CENTRALLY ACTING MUSCLE RELAXANTS/|MUSCLE RELAXANTS CAUSE SKELETAL MUSCULAR RELAXATION, WITHOUT LOSS OF CONSCIOUSNESS, AS RESULT OF SELECTIVE ACTION UPON CNS. ... ALL TYPES OF EXPTL HYPERTONIA & HYPERREFLEXIA...PRODUCED BY SPINAL OR SUPRASPINAL LESIONS, ARE DIMINISHED... ALSO...PROTECTION AGAINST...CONVULSIVE AGENTS... /CENTRALLY ACTING MUSCLE RELAXANTS/|...AS EFFECTIVE AS CHLORDIAZEPOXIDE IN TREATING MILD ANXIETY. MUSCULOSKELETAL DISORDERS IN WHICH ANXIETY & TENSION INTENSIFY SYMPTOMS MAY RESPOND TO ITS SEDATIVE EFFECT...DOES NOT APPEAR TO HAVE ANY SPECIFIC EFFECT ON SPASTICITY OR RIGIDITY ASSOC WITH ORG NEUROLOGIC DISORDERS.
SOMETIMES METABOLITE DISCOLORS URINE.|UNTOWARD EFFECTS ARE GENERALLY MILD & OCCUR RELATIVELY INFREQUENTLY BUT, IN 2 CONTROLLED STUDIES, REACTIONS WERE MORE COMMON...THAN WITH CHLORDIAZEPOXIDE.|...PRODUCE SOME SEDATION, @ LEAST @ HIGHEST DOSES EMPLOYED CLINICALLY. /CENTRALLY ACTING MUSCLE RELAXANTS/
Chlormezanone is a non-benzodiazepine muscle relaxant. It was discontinued worldwide in 1996 by its manufacturer due to confirmed serious and rare cutaneous reactions (toxic epidermal necrolysis).
Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)|A heterogeneous group of drugs used to produce muscle relaxation, excepting the neuromuscular blocking agents. They have their primary clinical and therapeutic uses in the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. They have been used also for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in MULTIPLE SCLEROSIS. (From Smith and Reynard, Textbook of Pharmacology, 1991, p358) (See all compounds classified as Muscle Relaxants, Central.)
RAPIDLY ABSORBED FROM GI TRACT...EFFECT WITHIN 15 TO 30 MIN...DURATION OF ACTION OF 4 TO 6 HR...FREE DRUG & /4-CHLOROHIPPURIC ACID/ EXCRETED IN URINE /HUMAN, ORAL/...PRESENT IN HIGH CONCN IN KIDNEY, LIVER, MUSCLE, HEART, & BODY FAT, & IN LESSER CONCN IN LUNG & PLASMA /RATS, ORAL/.|AFTER ORAL ADMIN OF (14)C-CHLORMEZANONE, ABOUT 74% OF DOSE WAS EXCRETED INTO URINE OF RATS WITHIN 24 HR & 21% INTO URINE OF MICE WITHIN 2 HR. BILIARY EXCRETION OF RADIOACTIVITY WAS ABOUT 10% OF DOSE IN RATS.
CHLORMEZANONE...IS EXCRETED UNCHANGED IN HUMAN URINE & DOG BILE. FORMATION OF 4-CHLOROHIPPURIC ACID, MAJOR URINARY METABOLITE IN MAN, INVOLVES NON-ENZYMIC HYDROLYSIS, FOLLOWED BY OXIDATION & CONJUGATION OF 4-CHLOROBENZALDEHYDE PRODUCT OF HYDROLYSIS.|(14)C-CHLORMEZANONE, METABOLITES IN URINE OF RATS & MICE WERE P-CHLOROBENZOIC ACID, P-CHLOROHIPPURIC ACID, N-METHYL-P-CHLOROBENZAMIDE, 2-[N-METHYL-N-(P-CHLOROBENZOYL)]CARBAMOYLETHYLSULFONIC ACID, 3-SULFOPROPIONIC ACID & GLUCURONIDE OF P-CHLOROBENZOIC ACID.
Chlormezanone binds to central benzodiazepine receptors which interact allosterically with GABA receptors. This potentiates the effects of the inhibitory neurotransmitter GABA, increasing the inhibition of the ascending reticular activating system and blocking the cortical and limbic arousal that occurs following stimulation of the reticular pathways.|NEURONAL CONDUCTION, NEUROMUSCULAR TRANSMISSION, & MUSCLE EXCITABILITY ARE NOT DEPRESSED EXCEPT AFTER NEARLY LETHAL DOSES. PROMINENT EFFECT...IS TO DEPRESS SPINAL POLYSYNAPTIC REFLEXES PREFERENTIALLY OVER MONOSYNAPTIC REFLEXES. /CENTRALLY ACTING MUSCLE RELAXANTS/|IN ABSENCE OF DEFINITIVE STUDIES IT APPEARS REASONABLE TO ASCRIBE BENEFICIAL EFFECTS...TO THEIR SEDATIVE PROPERTIES. /CENTRALLY ACTING MUSCLE RELAXANTS/
...COMMONLY PRODUCE DROWSINESS, DIZZINESS, HEADACHE, BLURRED VISION, WEAKNESS, LETHARGY, ATAXIA, & NYSTAGMUS. NAUSEA, VOMITING, HEARTBURN, & ABDOMINAL DISTRESS...ESP AFTER LARGE ORAL DOES. ...SKIN RASH & PRURITUS &, RARELY, ANAPHYLACTOID REACTIONS & LEUKOPENIA. /CENTRALLY ACTING MUSCLE RELAXANTS/|INCIDENCE OF UNTOWARD REACTIONS IS ABOUT 3% & MINOR IN NATURE...MALAISE, EXCITEMENT... PETECHIAE, OR ECCHYMOSES SOMETIMES DEVELOP; LIVER DAMAGE...OR ANGIONEUROTIC EDEMA ARE RARE.|LETHARGY & FLUSHING HAVE BEEN OBSERVED & JAUNDICE HAS OCCURRED RARELY.|...ORAL TOXICITY LESS THAN MEPROBAMATE, ZOXAZOLAMINE, OR METHOCARBAMOL. ... IN CLINICAL TRIALS ONLY 2.3% OF 4653 PT HAS SIDE EFFECTS... OVERDOSAGE UP TO 10 G HAS NOT CAUSED DEATH. EVEN LARGE AMT PRODUCE ONLY MILD SIDE EFFECTS.
Chlormethazanone
(±)-Chlormezanone Use and Manufacturing
PREPN STARTING WITH 4-CHLOROBENZYLIDENEMETHYLAMINE: SURREY ET AL, J AM CHEM SOC 80, 3469 (1958): BRIT PAT 815,203 (1959 TO STERLING DRUG).
Skeletal muscle relaxant
ORAL: TABLETS 100 & 200 MG
QUALITATIVE GAS CHROMATOGRAPHIC ANALYSIS OF CHLORMEZANONE IN POSTMORTEM BLOOD, USING A NITROGEN PHOSPHORUS DETECTOR.
Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients|Pharmaceuticals
Computed Properties
Molecular Weight:273.74
XLogP3:1.1
Hydrogen Bond Acceptor Count:3
Rotatable Bond Count:1
Exact Mass:273.0226421
Monoisotopic Mass:273.0226421
Topological Polar Surface Area:62.8
Heavy Atom Count:17
Complexity:395
Undefined Atom Stereocenter Count:1
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes
Drug Function and Efficacy
Antianxiety drug, with weak sedative and muscle relaxant effects. The main sites of action are the thalamus, basal ganglia, limbic system, midbrain reticular formation, etc. It has no effect on the autonomic nerves, no anti-adrenergic and anti-cholinergic effects, and no significant effect on the circulatory system. It has little inhibitory effect on the monotactile reflex of the spinal cord, but a significant inhibitory effect on the complex reflex, thus showing a central muscle relaxant effect. It can improve the emotional state of moderate anxiety without consciousness clarity disorder.
Learn More Other Chemicals
-
1,1,1,3-TETRAFLUOROACETONE
359-43-3
-
Ergosterol
57-87-4
-
Rolapitant
552292-08-7
-
Atropine sulfate monohydrate Formula
5908-99-6
-
(-)-Lobeline hydrochloride Formula
134-63-4
-
(-)-Securinine Formula
5610-40-2
-
2,4,5-Trimethoxyamphetamine Structure
1083-09-6
-
Pilocarpine Structure
92-13-7
-
What is Benzphetamine hydrochloride
5411-22-3
-
What is Biperiden hydrochloride
1235-82-1